Variant of hepatitis B virus with primary resistance to adefovir.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16641397.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, Gilead). All three cases involved a rare HBV variant with a valine at position 233 of the reverse-transcriptase domain instead of isoleucine (rtI233V), as in the wild-type virus. This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir in vitro.
Medical subject headings
- Adenine
- Drug Resistance, Viral
- Hepatitis B virus
- Hepatitis B, Chronic
- Organophosphonates
- RNA-Directed DNA Polymerase
- Reverse Transcriptase Inhibitors